Molecular study of nasopharyngeal cancer treatment
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This study looks at the molecular features of nasopharyngeal carcinoma to find better ways to predict treatment success and identify new targets for therapy. It’s for people already treated at Union Hospital in Wuhan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with nasopharyngeal carcinoma (a type of head and neck cancer).
- You received treatment (radiotherapy, chemotherapy, and immunotherapy) at Union Hospital in Wuhan.
- You were diagnosed between January 2025 and December 2028.
- Your medical records are complete and available for review.
- You are between 15 and 75 years old.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a special analysis of blood markers and imaging scans can help doctors choose the best combination of chemotherapy and radiation for nasopharyngeal cancer. The goal is to improve outcomes by tailoring treatment to each patient's specific cancer characteristics.
This trial tests whether adjusting chemotherapy based on tumor markers (EBV-DNA) and MRI scans can improve outcomes and reduce side effects for people with nasopharyngeal cancer. If you have stage II or III disease, this study might help guide your treatment more precisely.
This study helps doctors predict which patients with nasopharyngeal cancer (a cancer of the upper throat) will benefit most from additional chemotherapy after radiation treatment. It uses a special blood test and imaging to create a personalized risk score for each patient.
This study is testing if a new blood test can help find nasopharyngeal cancer early. It compares different methods to see which works best. This could help people get diagnosed and treated sooner.
This trial tests a more precise form of radiation therapy (adaptive radiotherapy) for nasopharyngeal cancer. It is designed for patients who have not yet had any treatment and whose cancer is limited to the head and neck area.
This trial tests a combination of high and low dose radiation plus an immunotherapy drug (PD-1 inhibitor) for people whose nasopharyngeal cancer has come back after previous treatment. The goal is to see if this approach can be more effective while reducing side effects.
Hear when a new Nasopharyngeal Carcinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.